0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover624.48%IV-427.98%PremiumMay 16, 2025Expiry Date4.05Intrinsic Value100Multiplier10DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8525Delta0.2345Gamma0.23Leverage Ratio-0.0103Theta-0.0009Rho-0.20Eff Leverage0.0004Vega
Opus Genetics Stock Discussion
Breakthrough: New Gene Therapy Restores Vision in 16-Year-Old Patient Clinical Trial
Breakthrough Eye Treatment Shows 21% Success Rate in Phase 3 Trial for Night Vision Problems
Opus Genetics Scores FDA Fast Track Status: What This Means for Its Vision-Restoring Eye Drops
Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs
Wednesday, 26th February at 8:00 am
FDA Fast Track Designation granted for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night driving impairment in keratorefractive patients with reduced mesopic vision
Enrollment completion in LYNX-2 pivotal Phase 3 trial expected in first half of 2025
Enrollment now complete in VEGA-3 pivotal...
Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
Tuesday, 18th February at 7:30 am
First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025
New 12-month data on the first three adult OPGx-LCA5 patients to be presented at a major medical conference in Q2 2025
FDA meeting scheduled in March 2025 to discuss Phase 3 trial design and registrational endpoints for OPGx-LCA5
DURHAM, N.C.,...
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Thursday, 19th December at 8:00 am
Agreement Reached on Primary Endpoint and Phase 3 Trial Design
Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering
FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the tre...
📊⚡️📊
No comment yet